Thursday, August 25, 2011
Peregrine Pharmaceuticals Inc., of Tustin, Calif., reported that bavituximab in combination with docetaxel in patients with locally advanced or metastatic breast cancer demonstrated a 20.7 month median overall survival (OS) in a single-arm Phase II trial.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.